ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Four Cycles of CHOP Instead of Six for Favorable DLBCL Four Cycles of CHOP Instead of Six for Favorable DLBCL
Patients with favorable-prognosis DLBCL receiving four cycles of R-CHOP followed by two additional cycles of rituximab had outcomes similar to those in patients receiving six cycles.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ibrutinib Alone Wins in Older CLL Patients
(MedPage Today) -- Adding rituximab offered no added benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 1, 2018 Category: Hematology Source Type: news

Monthly News Roundup - November 2018
FDA Approves Truxima as the First Biosimilar to Rituxan In November, the U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) injection from Celltrion as the first biosimilar to Rituxan (rituximab) for the treatment of adult... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2018 Category: Pharmaceuticals Source Type: news

Outcomes and PFS at 24 Months for Patients With DLBCL Outcomes and PFS at 24 Months for Patients With DLBCL
The potential for positive survival outcomes is excellent in patients with DLBCL who have not progressed 24 months after receiving rituximab-containing immunochemotherapy.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

First Biosimilar Rituximab for Lymphoma Approved in US First Biosimilar Rituximab for Lymphoma Approved in US
Truxima, designed for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma, can be used as a single agent or in combination with chemotherapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Rituximab Biosimilar for NHL
(MedPage Today) -- Indications for front line or beyond, single agent or combination (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2018 Category: American Health Source Type: news

FDA approves first biosimilar to Roche's cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin ’s Lymphoma
November 28, 2018 -- The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. FDA approves first biosimilar to Roche's cancer drug Rituxan
The U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan available in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin ' s lymphoma drug Rituxan, the agency said today. Truxima, as with Rituxan, is approved to treat... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’ s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’ s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news